A randomized, prospective, double-blinded trial of cyclosporine vs. OG37-325 in cadaveric renal transplantation--a preliminary report.
The efficacy of cyclosporine is documented, but it has side effects that are troublesome. Another compound, OG37-325, has been identified that appears to have similar efficacy, but less nephrotoxicity. This study was designed to address the benefits and toxicities of cyclosporine and OG37-325 in a prospective, randomized, double-blinded trial in cadaveric renal transplant recipients. The preliminary results demonstrate similar outcomes in terms of patient and graft survival, but suggest less nephrotoxicity in the OG37-325-treated patients. Longer follow-up will delineate the utility of OG37-325 in solid-organ transplantation.
Henry
M L
ML
Department of Surgery, Ohio State University College of Medicine, Columbus 43210.
Tesi
R J
RJ
Elkhammas
E A
EA
Ferguson
R M
RM
D000328:Adult; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged
D003524:Cyclosporins; D007166:Immunosuppressive Agents; C045571:cyclosporin G; D016572:Cyclosporine